創薬サービスの世界市場：市場規模・シェア分析 (プロセス別・種類別・医薬品の種類別・治療領域別・エンドユーザー別)、産業の需要予測 (～2030年)

市場概要

世界の創薬サービスの市場規模は、2023年に210億米ドルと推計され、2030年には542億米ドルに達すると予測されています。また、2024年から2030年のCAGRは14.7%に相当します。

バイオ医薬品業界や製薬業界における研究開発投資の増加、分析試験施設のアウトソーシングニーズの高まり、希少医薬品や希少疾患研究のステップ、自社での医薬品開発にはコストがかかることなどが、世界の業界における新たな収益の門を開いています。

主要な洞察

2023年、創薬サービス業界では、ヒット・ツー・リード同定カテゴリーが35%の最大シェアを占めました。

2023年には、化学カテゴリーが市場で60%のトップシェアを占めています。

低分子医薬品のカテゴリーは業界で大きなシェアを占めており、世界の新規治療法の出現に不可欠です。低分子医薬品は特殊医薬品の売上の50%を占め、2020年のFDA承認の75%以上を占めています。

北米地域は、近年の医薬品開発サービスにおいて55%という最大の業界シェアを占めています。

当レポートでは、世界の創薬サービスの市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、プロセス別・種類別・医薬品の種類別・治療領域別・エンドユーザー別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：プロセス別 (2017～2030年)
• 市場収益：種類別 (2017～2030年)
• 市場収益：医薬品の種類別 (2017～2030年)
• 市場収益：治療領域別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：プロセス別 (2017～2030年)
• 市場収益：種類別 (2017～2030年)
• 市場収益：医薬品の種類別 (2017～2030年)
• 市場収益：治療領域別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ市場

第12章 米国市場

• 概要
• 市場収益：プロセス別 (2017～2030年)
• 市場収益：種類別 (2017～2030年)
• 市場収益：医薬品の種類別 (2017～2030年)
• 市場収益：治療領域別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Charles River Laboratories International Inc.
• Eurofins Scientific Limited
• Frontage Laboratories Inc.
• Galapagos NV
• General Electric
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Syngene International Limited
• WuXi AppTec

第31章 付録

Market Overview

In 2023, the estimated value of the global drug discovery services market is USD 21.0 billion, projected to reach USD 54.2 billion by 2030. This growth represents a Compound Annual Growth Rate of 14.7% during the period from 2024 to 2030.

The growing research and development investments of the biopharmaceutical and pharmaceutical industries, the increasing need for outsourcing analytical testing facilities, steps for orphan drug and rare illness research, and the costly nature of the in-house drug expansion procedure are all opening up new revenue gates in the worldwide industry.

One of the reasons for the escalating demand for outsourcing clinical testing and analytical research services for biopharmaceutical drugs is the rising expenditure of R&D activities that are majorly channelled toward orphan drugs that are meant to suppress rare conditions.

On the other hand, the biopharmaceutical industry has been growing exceptionally due to the ever-increasing demands for biologics and the invention of and manufacturing of several innovative and life-saving drugs. Moreover, the bioscience industry profits from the investment in research of the new covered drugs for common and rare diseases. The market of drug discovery is also solving the problem of patents' expiration as well as the growing need for biologics in emerging economies.

Key Insights

In 2023, the hit-to-lead identification category held the largest share of 35% in the drug discovery services industry.

This procedure is vital in initial drug research and includes outsourcing to attain economies of scale and effectiveness for medicinal businesses.

Pioneering in-silico methods such as computer-aided drug discovery and structure-based medication designs contribute to the development of this category.

High-throughput screening plays a major role in hit-to-lead identification, eased by improvements in robotics, liquid management, plate reader discovery, and computing power.

Because of the dedicated and expensive nature of HTS, several organizations, particularly those with limited backing, select to outsource such services to Contract Research Organizations for high-quality and lucrative solutions.

In 2023, the chemistry category grips a leading share of 60% in the market.

Besides drug discovery, medicinal chemistry provides action at every stage, starting from pre-clinical evaluation to the delivery of a drug candidate.

The medical chemistry market is growing as companies work to find new ways to outsource tasks such as R&D services.

Such growth is continuously fostered by an increase in the number of overhead costs incurred during the pharmaceutical discovery and development processes.

Small-molecule drugs category grips a substantial industry share and is vital in emerging novel treatments worldwide.

Small-molecule drugs account for 50% of specialty drug sales and comprised over 75% of all FDA approvals in 2020.

They play a critical role in treating cancer, autoimmune diseases, cardiovascular disorders, and respiratory conditions.

The North American region holds the largest industry share of 55% in the recent years in drug advancement services.

The region aids from several Contract Research Organizations and Contract Manufacturing Organizations backing key pharmaceutical and biopharmaceutical firms, contributing to industry growth.

Numerous newly developed drugs have their patents held in the U.S., additionally boosting the industry.

Reasons propelling industry development include an increasing elderly populace, growing occurrence of chronic illnesses, technical improvements in biotechnology and pharmaceutical industries, recognized reimbursement guidelines, advanced medicinal infrastructure, rising awareness of initial disease diagnosis, and the reequipment for better patient care.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by process
  • 1.4.2. Market size breakdown, by type
  • 1.4.3. Market size breakdown, by drug type
  • 1.4.4. Market size breakdown, by therapeutic area
  • 1.4.5. Market size breakdown, by end user
  • 1.4.6. Market size breakdown, by region
  • 1.4.7. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Process (2017-2030)
• 6.3. Market Revenue, by Type (2017-2030)
• 6.4. Market Revenue, by Drug Type (2017-2030)
• 6.5. Market Revenue, by Therapeutic Area (2017-2030)
• 6.6. Market Revenue, by End User (2017-2030)
• 6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Process (2017-2030)
• 7.3. Market Revenue, by Type (2017-2030)
• 7.4. Market Revenue, by Drug Type (2017-2030)
• 7.5. Market Revenue, by Therapeutic Area (2017-2030)
• 7.6. Market Revenue, by End User (2017-2030)
• 7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Process (2017-2030)
• 8.3. Market Revenue, by Type (2017-2030)
• 8.4. Market Revenue, by Drug Type (2017-2030)
• 8.5. Market Revenue, by Therapeutic Area (2017-2030)
• 8.6. Market Revenue, by End User (2017-2030)
• 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Process (2017-2030)
• 9.3. Market Revenue, by Type (2017-2030)
• 9.4. Market Revenue, by Drug Type (2017-2030)
• 9.5. Market Revenue, by Therapeutic Area (2017-2030)
• 9.6. Market Revenue, by End User (2017-2030)
• 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Process (2017-2030)
• 10.3. Market Revenue, by Type (2017-2030)
• 10.4. Market Revenue, by Drug Type (2017-2030)
• 10.5. Market Revenue, by Therapeutic Area (2017-2030)
• 10.6. Market Revenue, by End User (2017-2030)
• 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Process (2017-2030)
• 11.3. Market Revenue, by Type (2017-2030)
• 11.4. Market Revenue, by Drug Type (2017-2030)
• 11.5. Market Revenue, by Therapeutic Area (2017-2030)
• 11.6. Market Revenue, by End User (2017-2030)
• 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Process (2017-2030)
• 12.3. Market Revenue, by Type (2017-2030)
• 12.4. Market Revenue, by Drug Type (2017-2030)
• 12.5. Market Revenue, by Therapeutic Area (2017-2030)
• 12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Process (2017-2030)
• 13.3. Market Revenue, by Type (2017-2030)
• 13.4. Market Revenue, by Drug Type (2017-2030)
• 13.5. Market Revenue, by Therapeutic Area (2017-2030)
• 13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Process (2017-2030)
• 14.3. Market Revenue, by Type (2017-2030)
• 14.4. Market Revenue, by Drug Type (2017-2030)
• 14.5. Market Revenue, by Therapeutic Area (2017-2030)
• 14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Process (2017-2030)
• 15.3. Market Revenue, by Type (2017-2030)
• 15.4. Market Revenue, by Drug Type (2017-2030)
• 15.5. Market Revenue, by Therapeutic Area (2017-2030)
• 15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Process (2017-2030)
• 16.3. Market Revenue, by Type (2017-2030)
• 16.4. Market Revenue, by Drug Type (2017-2030)
• 16.5. Market Revenue, by Therapeutic Area (2017-2030)
• 16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Process (2017-2030)
• 17.3. Market Revenue, by Type (2017-2030)
• 17.4. Market Revenue, by Drug Type (2017-2030)
• 17.5. Market Revenue, by Therapeutic Area (2017-2030)
• 17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Process (2017-2030)
• 18.3. Market Revenue, by Type (2017-2030)
• 18.4. Market Revenue, by Drug Type (2017-2030)
• 18.5. Market Revenue, by Therapeutic Area (2017-2030)
• 18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Process (2017-2030)
• 19.3. Market Revenue, by Type (2017-2030)
• 19.4. Market Revenue, by Drug Type (2017-2030)
• 19.5. Market Revenue, by Therapeutic Area (2017-2030)
• 19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Process (2017-2030)
• 20.3. Market Revenue, by Type (2017-2030)
• 20.4. Market Revenue, by Drug Type (2017-2030)
• 20.5. Market Revenue, by Therapeutic Area (2017-2030)
• 20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Process (2017-2030)
• 21.3. Market Revenue, by Type (2017-2030)
• 21.4. Market Revenue, by Drug Type (2017-2030)
• 21.5. Market Revenue, by Therapeutic Area (2017-2030)
• 21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Process (2017-2030)
• 22.3. Market Revenue, by Type (2017-2030)
• 22.4. Market Revenue, by Drug Type (2017-2030)
• 22.5. Market Revenue, by Therapeutic Area (2017-2030)
• 22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Process (2017-2030)
• 23.3. Market Revenue, by Type (2017-2030)
• 23.4. Market Revenue, by Drug Type (2017-2030)
• 23.5. Market Revenue, by Therapeutic Area (2017-2030)
• 23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Process (2017-2030)
• 24.3. Market Revenue, by Type (2017-2030)
• 24.4. Market Revenue, by Drug Type (2017-2030)
• 24.5. Market Revenue, by Therapeutic Area (2017-2030)
• 24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Process (2017-2030)
• 25.3. Market Revenue, by Type (2017-2030)
• 25.4. Market Revenue, by Drug Type (2017-2030)
• 25.5. Market Revenue, by Therapeutic Area (2017-2030)
• 25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Process (2017-2030)
• 26.3. Market Revenue, by Type (2017-2030)
• 26.4. Market Revenue, by Drug Type (2017-2030)
• 26.5. Market Revenue, by Therapeutic Area (2017-2030)
• 26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Process (2017-2030)
• 27.3. Market Revenue, by Type (2017-2030)
• 27.4. Market Revenue, by Drug Type (2017-2030)
• 27.5. Market Revenue, by Therapeutic Area (2017-2030)
• 27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Process (2017-2030)
• 28.3. Market Revenue, by Type (2017-2030)
• 28.4. Market Revenue, by Drug Type (2017-2030)
• 28.5. Market Revenue, by Therapeutic Area (2017-2030)
• 28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Charles River Laboratories International Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Eurofins Scientific Limited
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Frontage Laboratories Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Galapagos NV
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. General Electric
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Laboratory Corporation of America Holdings
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Thermo Fisher Scientific Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Syngene International Limited
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. WuXi AppTec
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports